Trials / Completed
CompletedNCT03381170
An Extension of the TG1101-RMS201 Trial
An Open Label Extension of the TG1101-RMS201 Trial, for Subjects Currently Enrolled in TG1101-RMS201Treated With Ublituximab for Relapsing Forms of Multiple Sclerosis
- Status
- Completed
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 48 (actual)
- Sponsor
- TG Therapeutics, Inc. · Industry
- Sex
- All
- Age
- 18 Years – 55 Years
- Healthy volunteers
- Not accepted
Summary
This study evaluates the long term use of a single agent ublituximab, a novel monoclonal antibody, in patients with relapsing forms of multiple sclerosis
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| BIOLOGICAL | Ublituximab | Enrolled Subjects will be infused with ublituximab on Weeks 1E, 24E, 48E, 72E and 96E |
Timeline
- Start date
- 2017-06-01
- Primary completion
- 2022-11-11
- Completion
- 2022-11-11
- First posted
- 2017-12-21
- Last updated
- 2022-12-21
Locations
8 sites across 1 country: United States
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT03381170. Inclusion in this directory is not an endorsement.